Øystein Fluge, Ingrid G Rekeland, Katarina Lien, Hanne Thürmer, Petter C Borchgrevink, Christoph Schäfer, Kari Sørland, Jörg Aßmus, Irini Ktoridou-Valen, Ingrid Herder, Merethe E Gotaas, Øivind Kvammen, Katarzyna A Baranowska, Louis M L J Bohnen, Sissel S Martinsen, Ann E Lonar, Ann-Elise H Solvang, Arne E S Gya, Ove Bruland, Kristin Risa, Kine Alme, Olav Dahl, Olav Mella
BACKGROUND: Previous phase 2 trials indicated benefit from B-lymphocyte depletion in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). OBJECTIVE: To evaluate the effect of the monoclonal anti-CD20 antibody rituximab versus placebo in patients with ME/CFS. DESIGN: Randomized, placebo-controlled, double-blind, multicenter trial. (ClinicalTrials.gov: NCT02229942). SETTING: 4 university hospitals and 1 general hospital in Norway...
May 7, 2019: Annals of Internal Medicine